We advised Immatics on the offering

Davis Polk advised Immatics N.V. in connection with its SEC-registered direct offering of 15,535,100 ordinary shares at $8.69 per share and pre-funded warrants to purchase 4,315,304 ordinary shares at $8.689 per pre-funded warrant, for total gross proceeds of approximately $172.5 million. The shares sold included 2,589,184 ordinary shares sold pursuant to the underwriters’ over-allotment option. The ordinary shares are listed on Nasdaq under the symbol “IMTX.”

Immatics, a clinical-stage biopharmaceutical company, is the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers, and is committed to making a meaningful impact on the lives of patients with cancer. The company’s cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Hope Goimarac and Jonathan P. Trojan-Greenberg. Partner Ethan R. Goldman, counsel Dustin Plotnick and associate Fred (Chen) Fu provided tax advice. Counsel Matthew R. Silver and Sarah E. Kim and associate Rebecca Sattaur provided 1940 Act advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post